SEC Company Response from RESMED INC (RMD, RSMDF) (CIK 0000943819) (RMD) — Mar 29, 2021
RESMED INC (RMD, RSMDF) (CIK 0000943819)
Date: March 29, 2021 · CIK: 0000943819 · Accession: 0000943819-21-000006
AI Filing Summary & Sentiment
File numbers found in text: 001-15317
Letter
Office of Life Sciences Division of Corporation Finance Form 10-K for the Fiscal Year Ended June 30, 2020 File No. 001-15317 Filed August 13, 2020
Dear Mr. Burton,
ResMed (the “Company”, “we”, “us” or “our”) has the following response to the comment of the staff of the Division of Corporate Finance (the “Staff”) of the Securities Exchange Commission in its letter of February 26, 2021 relating to the above-referenced Annual Report on Form 10-K (the “10-K”). For your convenience, the Staff’s comment is reproduced below with the Company’s response immediately following.
Form 10-K for the Fiscal Year Ended June 30, 2020
Item 15 - Exhibits and Consolidated Financial Statement Schedules, page 89
1. “We note that there was no consent provided in Exhibit 23.1 as indicated. Please amend to file a consent signed by your independent registered certified public accounting firm. Refer to Item 601(b)(23)(i) of Regulation S-K.”
Response: In response to the Staff’s comment, we have filed an amendment to the 10-K to include a written consent from our independent auditors as an exhibit.
We acknowledge the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the Staff.
If you would like to discuss or have any additional questions or concerns, I can be contacted at +61 2 8884 2090.
Very truly yours,
ResMed Inc.
Show Raw Text
CORRESP 1 filename1.htm 0200630 10KA - SEC Response Letter March 29, 2021 Mr. David Burton Office of Life Sciences Division of Corporation Finance U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: ResMed Inc. Form 10-K for the Fiscal Year Ended June 30, 2020 File No. 001-15317 Filed August 13, 2020 Dear Mr. Burton, ResMed (the “Company”, “we”, “us” or “our”) has the following response to the comment of the staff of the Division of Corporate Finance (the “Staff”) of the Securities Exchange Commission in its letter of February 26, 2021 relating to the above-referenced Annual Report on Form 10-K (the “10-K”). For your convenience, the Staff’s comment is reproduced below with the Company’s response immediately following. Form 10-K for the Fiscal Year Ended June 30, 2020 Item 15 - Exhibits and Consolidated Financial Statement Schedules, page 89 1. “We note that there was no consent provided in Exhibit 23.1 as indicated. Please amend to file a consent signed by your independent registered certified public accounting firm. Refer to Item 601(b)(23)(i) of Regulation S-K.” Response: In response to the Staff’s comment, we have filed an amendment to the 10-K to include a written consent from our independent auditors as an exhibit. We acknowledge the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the Staff. If you would like to discuss or have any additional questions or concerns, I can be contacted at +61 2 8884 2090. Very truly yours, ResMed Inc. …………………………………………….. Brett Sandercock Chief Financial Officer ResMed Pty Limited 1 Elizabeth Macarthur Drive Bella Vista NSW 2153 Australia T +61 (2) 8884 1000 F +61 (2) 8884 2000 E ABN 30 003 765 142 ResMed.com